Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TRAIL-R4 (human) monoclonal antibody (01)

 
ALX-804-915-0100 100 µg 402.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:TRAIL receptor 4, DcR2, Death Receptor 2, TRUNDD, CD264, TNFRSF 10D, TNF-related apoptosis-inducing ligand receptor 4, Tumor necrosis factor receptor superfamily member 10D
 
Clone:01
 
Host:Mouse
 
Isotype:IgG1
 
Immunogen:Recombinant human TRAIL-R4 (aa 1-210) IgG1 Fc fusion protein.
 
UniProt ID:Q9UBN6
 
Species reactivity:Human
 
Applications:Flow Cytometry, IHC (PS)
 
Recommended Dilutions/Conditions:Flow Cytometry (1:10-1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Formulation:Liquid. In PBS, pH 7.4.  Contains no preservatives.
 
Handling:Avoid freeze/thaw cycles.
 
Shipping:Blue Ice Not Frozen
 
Short Term Storage:+4°C
 
Scientific Background:TRAIL-R4 is a type 1 transmembrane receptor that exhibits a truncated cytoplasmic domain.
 
ALX-804-915 IHC
Immunohistochemistry staining of formalin fixed, paraffin-embedded human prostate tumor tissue using TRAIL-R2 (human), mAb (DJR2-2) at 1:50 dilution showing the positive staining in prostate carcinoma cells (63x).
Please mouse over
ALX-804-915 IHC

Related Products

TRAIL-R4 polyclonal antibody 

ICC, IHC, WB | Print as PDF
 
ADI-AAP-371-E 100 µg 356.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
TRAIL receptor
By biological activity:
TRAIL receptor Monoclonal antibody
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Product Flyers
TRAIL & TRAIL Receptors
TRAIL & TRAIL Receptors
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,